The FDA is looking for more data to support a new US drug application for a product called Certriad which combines two cholesterol meds -- Abbott's TriLipix and AstraZeneca's Crestor. TriLipix is a class of drugs called fibrages that boost "good" cholesterol and reduce triglycerides, a fat found in the blood stream, and "bad" cholesterol. Crestor is a statin that raises "good" HDL cholesterol while reducing "bad" HDL cholesterol. The new product is intended to treat dyslipikemia, which results from elevated cholesterol and triglycerides. More than 100 million Americans suffer from the disorder says The American Heart Association. The companies will continue to work with the FDA. Studies on the effectiveness of statins in the prevention of cardiovascular disease are ongoing. One of many was reported in Journal Watch Cardiology last August by Dr Harlan Krumholz It results came from of an analysis of 10 trials with over 70,000 subjects over an average of 4 years, mean age 63, mean baseline LDL level 140, 2/3rds were male., ¼ of those had diabetes. Mortality was 5.7% in the control groups and 5.1% in the statin group. Go to http://bit.ly/bqbdnc for more. The study concluded that statins can reduce the risk of cardiovascular events in those without cardiovascular disease.
Latest headlines
Tuesday, 30 March, 2010
New fibrage-statin combos work their way through the system
Subscribe to:
Post Comments (Atom)
1 comments: